AstraZeneca Pharma India Ltd reported a 31% increase in revenue for Q2 2024, totaling INR 4,080.0 million, contributing to a total H1 revenue of INR 7,955.2 million; the company also launched new products, Palivizumab and Tremelimumab, in October 202
AI Assistant
Astrazeneca Pharma India Ltd
2024
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.